Article

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single‑arm, open‑label trial

2025-09-23

Abstract excerpt

<title>Abstract</title> <p>Background We conducted a prospective, singlearm, openlabel trial to evaluate venlafaxine efficacy and safety in hormone receptor-positive breast cancer patients on tamoxifen experiencing moderatetosevere hot flashes. Methods Twenty patients received venlafaxine at 37.5 mg/day for 4 weeks, with optional escalation to 75 mg/day. Weekly hot flash scores, adverse events, and serum concentr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7ea622c-119a-5b1c-9147-5974a056037c
DOI: 10.21203/rs.3.rs-7522015/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single‑arm, open‑label trialDOI 10.21203/rs.3.rs-7522015/v1Read

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.Semantic proximity Read

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.Semantic proximity Read

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.Semantic proximity Read

Clinical and biomarker predictors of side effects from tamoxifen.Semantic proximity Read

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.Semantic proximity Read

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.Semantic proximity Read

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.Semantic proximity Read

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read

Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover StudySemantic proximity Read

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read